Abstract: Substituted quinolines containing a 1,2,4-triazole moiety were synthesized using reported methods. The molecular docking studies support the experimental results that these compounds are active against A. fumigatus and C. albicans where N-myristoyl transferase (NMT) and dihydrofolate reductase (DHFR), respectively, are the target enzymes. The analogues that contain methoxy and chloro substituents exhibit the best antifungal activity.
Introduction
The number of immuno-suppressed patients with transplants, cancer or AIDS is growing rapidly due to invasive mycosis. The increasing occurrence of fungal infections, particularly among AIDS patients motivate the search for better antifungal agents [1] [2] [3] [4] [5] [6] [7] . The commonly used antifungal agents are azoles, polyenes and echinocandins. Some organisms have developed resistance to these antifungal agents because of their side effects and/or drug-drug interactions. Oral antifungal agents with a novel mode of action and excellent bioavailability [8] are in demand. In this report, which is aimed at identifying novel antifungal agents, we focused on developing the scaffolds that would selectively inhibit the enzymes N-myristoyl transferase (NMT) and dihydrofolate reductase (DHFR) from fungal species.
N-myristoyl transferase (NMT) is a promising target for antifungal, antiparasitic, and anticancer agents. Many potent NMT inhibitors with antifungal, antiparasitic, and anticancer activities have been reported [9] . Inhibition of DHFR is a well-established mechanism of drug action [10] [11] [12] . The inability to synthesize DNA because of inhibition of DHFR can ultimately lead to cell death. To minimize DHFR related toxicities to the human host, the ideal antifungal agent should selectively inhibit the fungal enzyme. Such species-selective inhibition of DHFR has proven clinically useful in other therapeutic applications [13] [14] [15] [16] . For example, the therapeutic value of the antibacterial agent trimethoprim lies in its ability to selectively inhibit the bacterial enzyme. Certain pyrrolo-2,4-diaminoquinazolines 1 which are potent, but non-selective inhibitors of DHFR, have been reported to exhibit in vitro antifungal activity [17] . Other DHFR inhibitors include 5-methyl-6-alkyl-2,4-diaminoquinazolines 2 [18] and 6-substituted-2,4-diaminoquinazolines 3 [19] . Quinoline moiety is present in many synthetic and naturally occurring biologically active compounds [20, 21] . Quinolines possess antibacterial, anthelmintic, antimalarial, antifungal, cardiotonic, anticonvulsant, analgesic and anti-inflammatory activities [22] . Compounds 4-6, extracted from alkaloid Haplophylham sieversii are examples of antifungal agents [23] . 1,2,4-Triazoles are an important class of heterocyclic compounds that possess a broad spectrum of chemotherapeutic properties including antifungal, antiviral, anti-inflammatory, anti-proliferative, anti-asthmatic, hypnotic, pesticidal, antidepressant, and antimicrobial properties [24] [25] [26] .
In the present report, we have synthesized 2-(aryloxy)-quinolines carrying a 1,2,4-triazole moiety at position 3 spaced through a methylene group. The molecular docking study has been undertaken for the detailed study of the interaction of molecules for the inhibition of enzymes NMT and DHFR to aid in analysis of the antifungal activity. The in vitro antifungal activity of these compounds has been carried out against the pathogenic strains A. fumigatus and C. albicans.
Results and discussion
In our continuous effort to discover potent antifungal agents, 24 novel quinoline derivatives were synthesized and purified. 2-Aryl-2H-1,2,4-triazol-3(4H)-ones 3a,b were prepared from the corresponding N-arylsydnones 1a,b through the intermediary of 5-methyl-3-aryl-1,3,4-oxadiazol-2(3H)-ones 2a,b (Scheme 1) [24, 25] . 6-Substituted-2-chloro-3-formylquinolines 4c-f were prepared by Meth-Cohns' Vilsmeir-Haack approach and then converted to 6-substituted-2-aryloxy-quinoline-3-carbaldehydes 5g-r. Reduction of the formyl group with NaBH 4 followed by treatment with PBr 3 yielded 6-substituted-3-(bromomethyl)-2-aryloxyquinolines 7g-r [27] . The reaction of compounds 3a,b with compounds 7g-r in the presence of anhydrous K 2 CO 3 afforded the final products 2-aryl-4[{(6-substituted-2-(aryloxy)quinolin-3-yl) methyl}]-2H-1,2,4-triazol-3(4H)-ones 8-31 (Scheme 2). Predicted structures of the newly synthesized compounds were in good agreement with their IR, 1 H NMR, 13 C NMR, MS and elemental analysis data.
Docking simulation
Molecular docking was used to determine the orientation of inhibitors bound in the active sites of NMT and DHFR. The docking studies are in agreement with the experimental findings that compounds 22, 24 and 29 are good antifungal agents. As depicted in Figures 1 and 2 , compound 24 forms four hydrogen bonds at the active site of the enzyme NMT. The nitrogen atom of the quinoline forms hydrogen bond with hydrogen of SER378 (N-----H-SER378), the methoxy group present at ortho position of the phenoxyphenyl group and the methoxy group at para position of the phenyl ring attached to a triazole ring form two respective hydrogen bonds with hydrogen of ASN434 and ASN152 (H 3 CO-----H-ASN434 and H-ASN152) and the last hydrogen bond is the result of the interaction of the nitrogen atom of a triazole ring with hydrogen of GLY455 (N-----H-GLY455).
As depicted in Figures 1 and 2 , compound 29 makes two hydrogen bonds with the active site of the enzyme DHFR. These are interaction of the triazole with hydrogen of GLU116 (N-----H-GLU116) and interaction of the carbonyl group at the triazole with hydrogen of THR58 (C=O-----H-THR58). The docking study corroborates the experimental findings (Tables 1 and 2 ). As can be seen from the scores listed in Tables 1 and 2 , all molecules preferentially bind in the active sites of the enzymes in comparison with the references 4CAW and 1AI9. As depicted in Figures 3 and  4 , compound 22 is involved in three hydrogen bonding interactions with the enzyme (PDB ID: 1AI9). One is N-----H-GLU116 and the remaining two interactions involve the oxygen atom of a carbonyl group present at position 5 of the triazole ring with hydrogens of THR58 and GLY114 (C=O-----H-THR58 and C=O-----H-GLY114).
In vitro antifungal activity
The compounds were subjected to in vitro antifungal screening against pathogenic strains A. fumigatus and C. albicans using fluconazole as a standard drug (Table 3) . The experimental activity results parallel the results of docking simulation. 
Conclusions

Experimental
Melting points were determined in open capillary tubes and are uncorrected. All reactions were monitored by thin layer chromatography using silica gel pre-coated aluminium sheets (Merck TLC 60 F 254 ) and visualized in a UV light chamber. 2-Chloro-3-formylquinolines 4c-f and N-arylsydnones 1a,b were prepared according to the reported methods indicated in the text. IR spectra were recorded in KBr discs on a Nicolet 170 SX FT-IR spectrometer. 1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectra were recorded on a Bruker Advance FT NMR spectrometer in DMSO-d 6 with TMS as an internal standard. Mass spectra were recorded using a Finnegan MAT 8200 spectrometer.
General procedure for synthesis of compounds 8-31
A mixture of compound 3a,b (1.0 mmol), 7g-r (1.6 mmol) and anhydrous K 2 CO 3 (1.6 mmol) in DMF was stirred for 20 min at room temperature. After completion, ice-cold water was added and the resultant solid mass was filtered and recrystallized from ethyl acetate. 2-(2-Methoxyphenoxy)quinolin-3-yl)methyl}]-2-phenyl-2H-1,2,4-triazol-3(4H)-one (12 2-(4-Chlorophenoxy)-6-methylquinolin-3-yl)methyl}]-2-phenyl-2H-1,2,4-triazol-3(4H) -2-(4-chlorophenoxy)quinolin-3-yl)methyl}]-2-phenyl-2H-1,2,4-triazol-3(4H)-one (18 4-(6-Methoxy-2-(p-tolyloxy)quinolin-3-yl)methyl]-2-(4-methoxyphenyl)-2H-1,2,4-triazol-3(4H) 2-(2-Methoxyphenoxy)quinolin-3-yl)methyl]-2-(4-methoxyphenyl)-2H-1,2,4-triazol-3(4H)-one (24 157.0, 143.0, 141.0, 137.0, 135.0, 132.1, 131.0, 130.0 
[4-{(6-Methoxy-2-(2-methoxyphenoxy)quinolin-3-yl)methyl}]-2-phenyl-2H-1,2,4-triazol-3(4H)-one (15) This
Molecular docking studies
The crystal structures of NMT (A. fumigatus) in complex with myristoyl CoA and pyrazole sulphonamide ligand (PDB ID: 4CAW; A-Chain) and DHFR (PDB ID: 1AI9) (C. albicans) were used for the docking studies. These data were obtained from the Protein Data Bank. The proteins were prepared for docking by adding polar hydrogen atom with Gasteiger-Hückel charges and water molecules were removed. The 3D structure of the ligands was generated by the SKETCH module implemented in the SYBYL program (Tripos Inc., St. Louis, MO, USA) and its energy-minimized conformation was obtained with the help of the Tripos force field using Gasteiger-Hückel charges [28] . Molecular docking was performed with Surflex-Dock program that interfaced with Sybyl-X 2.0 [29] and other miscellaneous parameters were assigned to the default values given by the software.
In vitro antifungal activity assay
Dilutions of each sample are done with BHI (brain heart infusion) for MIC. In the initial tube, drug (20 μL) was added into the BHI (380 μL) broth. For dilutions, BHI broth (200 μL) was added into the next nine tubes separately. Then from the initial tube 200 μL was transferred to the first tube containing BHI broth (200 μL). This was a 10 −1 dilution. From 10 −1 diluted tube, 200 μL was transferred to the second tube to make 10 −2 dilution. The serial dilution was repeated up to 10 −9 dilution for each drug. From the maintained stock cultures of required organisms, a 5 μL-culture was taken and added into BHI (02 mL) broth. To each serially diluted tube, above culture suspension (200 μL) was added. The tubes were incubated for 24 h and observed for turbidity [30] .
